SELECTing adjuvant treatment in early stage epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer.
作者信息
Tabbò Fabrizio, Reale Maria Lucia, Ruffini Enrico, Novello Silvia, Guerrera Francesco
机构信息
Department of Oncology, Università degli Studi di Torino, Turin, Italy.
Department of Surgical Sciences, Università degli Studi di Torino, Turin, Italy.
出版信息
Ann Transl Med. 2019 May;7(9):190. doi: 10.21037/atm.2019.03.55.
Abstract
摘要
相似文献
1
SELECTing adjuvant treatment in early stage epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer.早期表皮生长因子受体（EGFR）阳性非小细胞肺癌辅助治疗的选择
Ann Transl Med. 2019 May;7(9):190. doi: 10.21037/atm.2019.03.55.
2
Epidermal growth factor receptor tyrosine kinase inhibitors in early-stage nonsmall cell lung cancer.表皮生长因子受体酪氨酸激酶抑制剂在早期非小细胞肺癌中的应用
Curr Opin Oncol. 2015 Mar;27(2):102-7. doi: 10.1097/CCO.0000000000000163.
3
Neoadjuvant and adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer.肺癌的新辅助和辅助表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）治疗。
Transl Lung Cancer Res. 2015 Feb;4(1):82-93. doi: 10.3978/j.issn.2218-6751.2014.11.08.
4
Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.表皮生长因子受体突变型非小细胞肺癌患者使用第一代表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）发生严重不良反应后切换使用第二代 EGFR-TKI 的临床影响。
Jpn J Clin Oncol. 2012 Jun;42(6):528-33. doi: 10.1093/jjco/hys042. Epub 2012 Mar 28.
5
Prognostic Factors for Survival After Recurrence in Patients With Completely Resected Lung Adenocarcinoma: Important Roles of Epidermal Growth Factor Receptor Mutation Status and the Current Staging System.完全切除的肺腺癌患者复发后生存的预后因素：表皮生长因子受体突变状态和现行分期系统的重要作用
Clin Lung Cancer. 2015 Nov;16(6):e213-21. doi: 10.1016/j.cllc.2015.04.005. Epub 2015 Apr 20.
6
Retrospective study of adjuvant icotinib in postoperative lung cancer patients harboring epidermal growth factor receptor mutations.回顾性研究表皮生长因子受体突变的肺癌术后辅助伊可替尼。
Thorac Cancer. 2016 Sep;7(5):543-548. doi: 10.1111/1759-7714.12365. Epub 2016 Jun 13.
7
Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial.厄洛替尼对比长春瑞滨联合顺铂用于表皮生长因子受体突变阳性的 IIIA 期非小细胞肺癌中国患者的辅助治疗（EVAN）：一项随机、开放标签、二期临床试验。
Lancet Respir Med. 2018 Nov;6(11):863-873. doi: 10.1016/S2213-2600(18)30277-7. Epub 2018 Aug 24.
8
Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics.用于表皮生长因子受体基因突变阳性非小细胞肺癌的酪氨酸激酶抑制剂：治疗学最新进展
J Oncol Pharm Pract. 2016 Jun;22(3):461-76. doi: 10.1177/1078155215577810. Epub 2015 Apr 8.
9
A Retrospective Study of Stage I to IIIa Lung Adenocarcinoma After Resection: What Is the Optimal Adjuvant Modality for Patients With an EGFR Mutation?I至IIIa期肺腺癌切除术后的回顾性研究：对于表皮生长因子受体（EGFR）突变患者，最佳辅助治疗方式是什么？
Clin Lung Cancer. 2015 Nov;16(6):e173-81. doi: 10.1016/j.cllc.2015.04.002. Epub 2015 Apr 20.
10
Gefitinib Versus Adjuvant Chemotherapy in Patients With Stage II-IIIA Non-Small-Cell Lung Cancer Harboring Positive EGFR Mutations: A Single-Center Retrospective Study.表皮生长因子受体突变阳性的 II-IIIA 期非小细胞肺癌患者中吉非替尼对比辅助化疗的疗效：一项单中心回顾性研究。
Clin Lung Cancer. 2018 Nov;19(6):484-492. doi: 10.1016/j.cllc.2018.05.007. Epub 2018 May 26.
本文引用的文献
1
SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.选择：表皮生长因子受体突变型非小细胞肺癌患者术后辅助厄洛替尼的 II 期临床试验。
J Clin Oncol. 2019 Jan 10;37(2):97-104. doi: 10.1200/JCO.18.00131. Epub 2018 Nov 16.
2
Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial.厄洛替尼对比长春瑞滨联合顺铂用于表皮生长因子受体突变阳性的 IIIA 期非小细胞肺癌中国患者的辅助治疗（EVAN）：一项随机、开放标签、二期临床试验。
Lancet Respir Med. 2018 Nov;6(11):863-873. doi: 10.1016/S2213-2600(18)30277-7. Epub 2018 Aug 24.
3
Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?在 EGFR 驱动或 ALK 驱动的 NSCLC 中先行一步：选择第一代还是下一代 TKI？
Nat Rev Clin Oncol. 2018 Nov;15(11):694-708. doi: 10.1038/s41571-018-0081-4.
4
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.吉非替尼对比长春瑞滨联合顺铂作为 EGFR 突变型 II-IIIA 期（N1-N2）可切除 NSCLC（ADJUVANT/CTONG1104）的辅助治疗：一项随机、开放标签、III 期研究。
Lancet Oncol. 2018 Jan;19(1):139-148. doi: 10.1016/S1470-2045(17)30729-5. Epub 2017 Nov 21.
5
Lung cancer's real adjuvant EGFR targeted therapy questions.肺癌真正的辅助性表皮生长因子受体靶向治疗问题。
Lancet Oncol. 2018 Jan;19(1):15-17. doi: 10.1016/S1470-2045(17)30875-6. Epub 2017 Nov 21.
6
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.奥希替尼治疗未经治疗的 EGFR 突变型晚期非小细胞肺癌。
N Engl J Med. 2018 Jan 11;378(2):113-125. doi: 10.1056/NEJMoa1713137. Epub 2017 Nov 18.
7
Efficacy of EGFR Tyrosine Kinase Inhibitors in the Adjuvant Treatment for Operable Non-small Cell Lung Cancer by a Meta-Analysis.EGFR 酪氨酸激酶抑制剂在可手术非小细胞肺癌辅助治疗中的疗效：一项荟萃分析。
Chest. 2016 Jun;149(6):1384-92. doi: 10.1016/j.chest.2015.12.017. Epub 2015 Dec 24.
8
Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial.厄洛替尼辅助治疗与安慰剂对照用于 IB 期-IIIA 期非小细胞肺癌患者（RADIANT）：一项随机、双盲、III 期临床试验。
J Clin Oncol. 2015 Dec 1;33(34):4007-14. doi: 10.1200/JCO.2015.61.8918. Epub 2015 Aug 31.
9
Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study.吉非替尼对比安慰剂用于完全切除的非小细胞肺癌：NCIC CTG BR19 研究结果。
J Clin Oncol. 2013 Sep 20;31(27):3320-6. doi: 10.1200/JCO.2013.51.1816. Epub 2013 Aug 26.
10
Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data.可手术和局部晚期肺癌化疗和放疗试验中总生存的替代终点：对个体患者数据荟萃分析的重新分析。
Lancet Oncol. 2013 Jun;14(7):619-26. doi: 10.1016/S1470-2045(13)70158-X. Epub 2013 May 14.
Zotero 插件